A meaty sell off in banks, technology large cap stocks dragged down the ASX200 to its worst performance since April, while gold stocks continued to shine
Michael Gable of Fairmont Equities highlights the October pull back in Evolution Mining shares and subsequent consolidation has created a positive platform from which shares can rise again
Fisher & Paykel Healthcare’s first half saw lower costs overcoming a drag from US tariffs. Declining US vaccination rates could provide a boost in the second half
Gentrack’s FY25 results calmed investor concerns with the future stock re-rating reliant on converting a robust pipeline to new contract wins, albeit delayed
Web Travel’s interim results provide analysts with increased confidence in management achieving FY27 goals
Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements
FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments
Why 200 Companies Define Australian Investment Reality (and why they don’t)
A glance through the latest expert views and predictions about commodities: Boost to lithium demand; rare earths and selective floor pricing; global steel production; mid-tier gold picks
New research shows a strong growth outlook for renewable energy business LGI which provides exposure to the decarbonisation theme
